产品说明书

ChX710

Print
Chemical Structure| 2438721-44-7 同义名 : -
CAS号 : 2438721-44-7
货号 : A1365261
分子式 : C18H21N5O
纯度 : 99%+
分子量 : 323.392
MDL号 : MFCD32690078
存储条件：

粉末 Inert atmosphere,2-8°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 18 mg/mL(55.66 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H2O: 50 mg/mL(154.61 mM)，配合低频超声助溶
动物实验配方：
生物活性
描述 Interferon-stimulated genes (ISGs) are the effectors of interferon (IFN) actions and play major roles in innate immune defense against microbial infection. During virus infection, ISGs impart antiviral actions to control virus replication and spread but can also contribute to disease pathology if their expression is unchecked[2]. Type I interferons (IFNs) facilitate cancer immunosurveillance, antitumor immunity and antitumor efficacy of conventional cell death-inducing therapies (chemotherapy/radiotherapy) as well as immunotherapy[3]. IFNs bind to their cognate receptors on the cellular membrane and activate the signaling pathway for transcriptional regulation of ISGs through Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway[4]. JAK-STAT signaling mediates almost all immune regulatory processes, including those that are involved in tumor cell recognition and tumor-driven immune escape. Antitumor immune responses are largely driven by STAT1 and STAT2 induction of type I and II IFNs and the downstream programs IFNs potentiate[5]. ChX710 could prime the type I interferon response to cytosolic DNA, which specific cellular ISGs, induces the ISRE promoter sequence, and the phosphorylation of IRF3.The treatment of ChX710 efficiently prime the cellular response to DNA transfection via STING as assessed by strong synergistic effects on IFN-β expression at both transcriptional and protein levels[6].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

3.09mL

0.62mL

0.31mL

15.46mL

3.09mL

1.55mL

30.92mL

6.18mL

3.09mL
参考文献

[1]Khiar S, Lucas-Hourani M, Nisole S, Smith N, Helynck O, Bourgine M, Ruffié C, Herbeuval JP, Munier-Lehmann H, Tangy F, Vidalain PO. Identification of a small molecule that primes the type I interferon response to cytosolic DNA. Sci Rep. 2017 May 31;7(1):2561. doi: 10.1038/s41598-017-02776-z. PMID: 28566766; PMCID: PMC5451460.

[2] Richard Green,et al. Interferon-stimulated genes: new platforms and computational approaches. Mamm Genome. 2018 Aug;29(7-8):593-602.

[3]Jenny Sprooten,et al. Type I interferons and dendritic cells in cancer immunotherapy. Int Rev Cell Mol Biol. 2019;348:217-262.

[4]Mohsan Ullah Goraya,et al. Web of interferon stimulated antiviral factors to control the influenza A viruses replication. Microb Pathog.2020 Feb;139:103919.

[5] Katie L Owen,et al. JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression. Cancers (Basel). 2019 Dec 12;11(12):2002.

[6]Khiar S, et al. Identification of a small molecule that primes the type I interferon response to cytosolic DNA. Sci Rep. 2017 May 31;7(1):2561.